Latest filing published 22 Feb 2023 for BIOVIE INC., €14k.
Insider track record
No signal scores available.
Christopher Reading: trading record in brief
Filings by Christopher Reading span 2 companies, the busiest being Hollis Eden Pharmaceuticals Inc /DE/ and Biovie Inc. Over a trading history stretching from 13 February 2006 to 16 February 2023, the count stands at 9 filings.
No open-market purchase appears, only 6 sales worth €3,923. The rest of the record consists of 3 share grants.
The latest filing, published on 22 February 2023, reports a share grant of €14k in Biovie Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 1 day. For comparison, the SEC allows two business days to file a Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to Christopher Reading
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 2,476 shares@ US$6.12100.0% of flowCOMMON STOCKSEC:0001520138-23-000110:0
- 39,624 shares0COMMON STOCKSEC:0001520138-23-000058:0
- 93 shares@ US$5.46Common StockSEC:0001181431-07-011959:0
- 186 shares@ US$5.48Common StockSEC:0001181431-07-011959:1
- 193 shares@ US$5.49Common StockSEC:0001181431-07-011959:2
- 186 shares@ US$5.50Common StockSEC:0001181431-07-011959:3
- 186 shares@ US$5.52Common StockSEC:0001181431-07-011959:4
- 93 shares@ US$5.57Common StockSEC:0001181431-07-011959:5
- 3,750 shares0Common StockSEC:0001181431-06-011939:0
9 of 9 declarations
